摘要
目的探讨利培酮与丁螺环酮分别合并帕罗西汀治疗难治性抑郁症（TRD）的疗效及社会功能的比较。方法将91例TRD患者随机分配至帕罗西汀＋利培酮组或帕罗西汀＋丁螺环酮组进行双盲对照治疗8周，分别于基线、4周末、8周末评定17项汉密顿抑郁量表（HAMD-17），于基线、8周末评定社会功能缺陷筛选量表（SDSS）。结果治疗前后比较：两组治疗方案HAMD-174周末、8周末评分与基线比较以及4周末减分与8周末减分比较差异均有统计学意义（P≤0．001）。SDSS8周末评分与基线比较差异有统计学意义（P〈0．001）。组间比较：两组间HAMD-17评分基线、4周末、8周末、4周末减分及8周末减分比较均无统计学差异。SDSS基线、8周末评分差异无统计学意义，但SDSS8周末减分帕罗西汀＋利培酮组优于帕罗西汀＋丁螺环酮组（P〈0．05）。结论帕罗西汀＋利培酮与帕罗西汀＋丁螺环酮均能明显改善TRD的临床症状、提高社会功能，但利培酮＋帕罗西汀在提高社会功能方面明显优于丁螺环酮＋帕罗西汀。
Objective To compare the efficacy and social function improvement of paroxetine with risperidone or with buspirone in patients with treatment--resistant depression （TRD）. Methods 91 patients with TRD were randomly assigned to receive paroxetine plus risperidone or buspirone treatment for 8 weeks. The efficacy and social function improvement were evaluated with HAMD--17 and SDSS. Resuits There were significant differences in HAMD--17 scores between both two treatment group in 4th week and 8th week, and the subtracting scores between 4 weeks and 8 weeks （P ≤ 0. 001）, same for SDSS scores between 8th week and the baseline （P ≤0. 001）. There were no statistical significances between two treatment strategies in HAMD--17 scores and SDSS scores at baseline and the 8th week. But regarding SDSS subtracting scores at 8 weeks there was statistical difference in the risperidone ＋ paroxetine group versus buspirone ＋ paroxetine group. Conclusions The two treatment strategies both can significantly improve clinical symptoms in patients with TRD. However, regarding social function improvement the group augmenting paroxetine with risperidone was superior to the group with buspirone.
出处
《神经疾病与精神卫生》
2012年第4期332-334,共3页
Journal of Neuroscience and Mental Health
基金
基金项目：国家“十五”科技攻关项目（2004BA720A21-02）,卫生行业科研专项（201002003）
作者简介
通讯作者：卢卫红Email：luweihongdoctor@yahoo．cn
方贻儒Email：yirufang@yahoo．com．cn
